This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
NCT06451497
This study is recruiting at 3 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Toripalimab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Pancreas Adenocarcinoma
- Biliary Tract Cancer
- Prostate Cancer
- Urothelial Carcinoma
- Colorectal Cancer
- Triple Negative Breast Cancer
- High Grade Ovarian Serous Adenocarcinoma
- Diffuse Large B Cell Lymphoma
- Renal Cell Cancer Metastatic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Zumutor Biologics Inc.
- Last updated on ClinicalTrials.gov
- April 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
Texas · 2
- NEXT Oncology · Austin, TX 78758, TX
- NEXT Oncology · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.